In early September 2021, the US. Food and Drug Administration delivered an ominous message: all approved JAK inhibitors that treat inflammatory diseases now require a black box warning containing information about the risks of serious heart-related events, cancer, blood clots, and death. The FDA advises healthcare professionals (HCPs) to consider the benefits and risks of such therapies for each individual patient, with special attention given to smokers and those with other cardiovascular risk factors or known malignancies.

Brand marketers were concerned with whether or not to address the black box warning head on—emphasizing that their own product had not shown any increased risks but was simply part of a broader therapeutic class.

Several brands approached ZoomRx. This case study shows how ZoomRx’s HCP-Patient research helped brands get an authentic view of the situation and make decisions around their JAK product.

ZoomRx uses the info you provide to fulfill your request and contact you about relevant insights, products, and services. You may unsubscribe from all communications at any time. For more information, view our full privacy policy